Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine

Canadian Journal of Hospital Pharmacy

Volumn 66, Issue 2, 2013, Pages 125-129

  Bates, Duane ^a   Dalton, Bruce ^a   Gilmour, Janet ^a   Kapler, Jeff ^b  

^a FOOTHILLS HOSPITAL   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; CELECOXIB; DALTEPARIN; GABAPENTIN; HEPARIN; HYDROCHLOROTHIAZIDE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LAMOTRIGINE; LISINOPRIL; METOPROLOL; NEVIRAPINE; OMEPRAZOLE; RIVAROXABAN; TINZAPARIN; WARFARIN; ZIDOVUDINE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEG SWELLING; MALE; MEDICAL HISTORY; THORAX PAIN; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 84889015427     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery. Ann Pharmacother. 2012;46(9):1232-8.
2. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86. (Pubitemid 351930852)
3. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-80.
4. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010;44(6):1061-71.
5. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S-e325S.
6. Facts and comparisons: eAnswers [database on Internet]. Indianapolis (IN): Wolters Kluwer Health, Inc; 2012 [cited 2012 Sep 21]. Available from: http://online.factsandcomparisons.com. Subscription required to access content.
7. Micromedex 2.0® healthcare series [database on intranet]. Version 5.1. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc; 2012 [cited 2012 Sep 21]. Available from: www.thomsonhc.com. Subscription required to access content.
8. YouScript [personalized prescribing system on Internet]. Version 1.0. Seattle (WA): Genelex Corp; 2012 [cited 2012 Sep 21]. Available from: https://www.youscript.net/. Subscription required to access content.
9. Baxter K, editor. Stockley's drug interactions. 9th ed. London (UK): Royal Pharmaceutical Society; 2010.
10. Drug interaction tables. Toronto (ON): University Health Network, Toronto General Hospital, Immunodeficiency Clinic; 2012 [cited 2012 Sep 21]. Available from: www.hivclinic.ca/main/drugs-interact.html
11. McNicholl IR. Database of antiretroviral drug interactions [database on Internet]. San Francisco (CA): University of California, San Francisco, Center for HIV Information; 2012 [cited 2012 Sep 21]. Available from: http://hivinsite.ucsf.edu/InSite?page=ar-00-02
12. Lexicomp online [database on Internet]. Hudson (OH): Lexi-Comp, Inc; 2012 [cited 2012 Sep 18]. Available from: http://online.lexi.com. Subscription required to access content.
13. Xarelto [rivaroxaban] product monograph. Toronto (ON): Bayer Inc; 2012 Jul 18.
14. Drug interaction charts. Liverpool (UK): University of Liverpool; 2012 [cited 2012 Sep 21]. Available from: www.hiv-druginteractions.org
15. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-80. (Pubitemid 46625492)
16. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211-21.
17. Bates D, Burak KW, Coffin CS, Ying T, Enns EM. Phenytoin-induced reduction in sirolimus levels. Can J Hosp Pharm. 2011;64(4):271-4.
18. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011;31(12):1175-91.
19. Viramune [nevirapine] product monograph. Burlington (ON): Boehringer Ingelheim Canada; 2011 May 30.
20. Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11):2479-86. (Pubitemid 41727165)
21. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012;130(6):956-66.
22. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129(4):492-8.
23. Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675-86.
24. Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother. 2009;43(2):322-8.
25. Eliquis [apixaban] product monograph. Montreal (QC): Bristol-Myers Squibb Canada; 2012 Nov 27.
26. Burness CB, McKeage K. Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2012;72(7):963-86.
27. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society - USA panel. JAMA. 2012;308(4):387-402.
28. Kiser KL, Badowski ME. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy. 2010;30(12):1292-302.